Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Aug 2019 to Aug 2024
![Click Here for more Affymetrix Charts. Click Here for more Affymetrix Charts.](/p.php?pid=staticchart&s=N%5EAFFX&p=8&t=15)
Affymetrix Inc. (Nasdaq: AFFX) announced today that Wyeth (NYSE: WYE)
has signed another agreement with Affymetrix to use GeneChip®
microarray technology for three more years, further extending the
relationship that began in 1994. Under the agreement, Wyeth will
continue to apply Affymetrix technology in numerous areas of the drug
discovery and development process.
Wyeth was one of the first pharmaceutical companies to apply genomics in
clinical research. The company will continue to use Affymetrix
microarray technology to identify new drug targets and gain a better
understanding of the genetic markers that potentially correlate with a
patient’s response to therapy. The latest
GeneChip technology enables them to more accurately classify disease,
predict clinical progression and determine likelihoods of treatment
success in ways never before possible.
“Wyeth has been a pioneer in demonstrating the
power of Affymetrix microarray technology in the entire drug discovery
and development process,” said Chip Leveille,
vice president, Pharmaceutical Business Unit at Affymetrix. “We
anticipate that a better understanding of human genetic variations and
the ability to look at the entire genome in greater detail will
dramatically accelerate research and, ultimately, help bring more
effective tests and therapies to market faster.”
About Affymetrix
Affymetrix scientists invented the world's first high-density microarray
in 1989 and began selling the first commercial microarray in 1994. Since
then, Affymetrix GeneChip®
technology has become the industry standard in molecular biology
research. Affymetrix technology is used by the world's top
pharmaceutical, diagnostic and biotechnology companies as well as
leading academic, government and not-for-profit research institutes.
More than 1,400 systems have been installed around the world and more
than 7,000 peer-reviewed papers have been published using the
technology. Affymetrix' patented photolithographic manufacturing process
provides the most information capacity available today on an array,
enabling researchers to use a whole-genome approach to analyzing the
relationship between genetics and health. Affymetrix is headquartered in
Santa Clara, Calif., with manufacturing facilities in Sacramento,
Calif., and Bedford, Mass. The company maintains important sales and
marketing operations in Europe and Asia and has about 1,100 employees
worldwide. For more information about Affymetrix, please visit the
company's website at www.affymetrix.com.
All statements in this press release that are not historical are
"forward-looking statements" within the meaning of Section 21E of the
Securities Exchange Act as amended, including statements regarding
Affymetrix' "expectations," "beliefs," "hopes," "intentions,"
"strategies," or the like. Such statements are subject to risks and
uncertainties that could cause actual results to differ materially for
Affymetrix from those projected, including, but not limited to: risks
and uncertainties associated with the agreement between Affymetrix and
Wyeth discussed in this press release; risks of the Company's ability to
achieve and sustain higher levels of revenue, higher gross margins,
reduced operating expenses; uncertainties relating to technological
approaches, manufacturing, product development; personnel retention;
uncertainties related to cost and pricing of Affymetrix products;
dependence on collaborative partners; uncertainties relating to sole
source suppliers; uncertainties relating to FDA and other regulatory
approvals; competition; risks relating to intellectual property of
others and the uncertainties of patent protection and litigation. These
and other risk factors are discussed in Affymetrix' Form 10-K/A for the
year ended December 31, 2005, and other SEC reports, including its
Quarterly Reports on Form 10-Q for subsequent quarterly periods.
Affymetrix expressly disclaims any obligation or undertaking to release
publicly any updates or revisions to any forward-looking statements
contained herein to reflect any change in Affymetrix' expectations with
regard thereto or any change in events, conditions or circumstances on
which any such statements are based.
NOTE: Affymetrix, the Affymetrix logo, and GeneChip are registered
trademarks owned or used by Affymetrix Inc.
Affymetrix Inc. (Nasdaq: AFFX) announced today that Wyeth (NYSE:
WYE) has signed another agreement with Affymetrix to use GeneChip(R)
microarray technology for three more years, further extending the
relationship that began in 1994. Under the agreement, Wyeth will
continue to apply Affymetrix technology in numerous areas of the drug
discovery and development process.
Wyeth was one of the first pharmaceutical companies to apply
genomics in clinical research. The company will continue to use
Affymetrix microarray technology to identify new drug targets and gain
a better understanding of the genetic markers that potentially
correlate with a patient's response to therapy. The latest GeneChip
technology enables them to more accurately classify disease, predict
clinical progression and determine likelihoods of treatment success in
ways never before possible.
"Wyeth has been a pioneer in demonstrating the power of Affymetrix
microarray technology in the entire drug discovery and development
process," said Chip Leveille, vice president, Pharmaceutical Business
Unit at Affymetrix. "We anticipate that a better understanding of
human genetic variations and the ability to look at the entire genome
in greater detail will dramatically accelerate research and,
ultimately, help bring more effective tests and therapies to market
faster."
About Affymetrix
Affymetrix scientists invented the world's first high-density
microarray in 1989 and began selling the first commercial microarray
in 1994. Since then, Affymetrix GeneChip(R) technology has become the
industry standard in molecular biology research. Affymetrix technology
is used by the world's top pharmaceutical, diagnostic and
biotechnology companies as well as leading academic, government and
not-for-profit research institutes. More than 1,400 systems have been
installed around the world and more than 7,000 peer-reviewed papers
have been published using the technology. Affymetrix' patented
photolithographic manufacturing process provides the most information
capacity available today on an array, enabling researchers to use a
whole-genome approach to analyzing the relationship between genetics
and health. Affymetrix is headquartered in Santa Clara, Calif., with
manufacturing facilities in Sacramento, Calif., and Bedford, Mass. The
company maintains important sales and marketing operations in Europe
and Asia and has about 1,100 employees worldwide. For more information
about Affymetrix, please visit the company's website at
www.affymetrix.com.
All statements in this press release that are not historical are
"forward-looking statements" within the meaning of Section 21E of the
Securities Exchange Act as amended, including statements regarding
Affymetrix' "expectations," "beliefs," "hopes," "intentions,"
"strategies," or the like. Such statements are subject to risks and
uncertainties that could cause actual results to differ materially for
Affymetrix from those projected, including, but not limited to: risks
and uncertainties associated with the agreement between Affymetrix and
Wyeth discussed in this press release; risks of the Company's ability
to achieve and sustain higher levels of revenue, higher gross margins,
reduced operating expenses; uncertainties relating to technological
approaches, manufacturing, product development; personnel retention;
uncertainties related to cost and pricing of Affymetrix products;
dependence on collaborative partners; uncertainties relating to sole
source suppliers; uncertainties relating to FDA and other regulatory
approvals; competition; risks relating to intellectual property of
others and the uncertainties of patent protection and litigation.
These and other risk factors are discussed in Affymetrix' Form 10-K/A
for the year ended December 31, 2005, and other SEC reports, including
its Quarterly Reports on Form 10-Q for subsequent quarterly periods.
Affymetrix expressly disclaims any obligation or undertaking to
release publicly any updates or revisions to any forward-looking
statements contained herein to reflect any change in Affymetrix'
expectations with regard thereto or any change in events, conditions
or circumstances on which any such statements are based.
NOTE: Affymetrix, the Affymetrix logo, and GeneChip are registered
trademarks owned or used by Affymetrix Inc.